早期乳腺癌保乳治疗患者美容效果不良的预测因素:Young Boost 试验结果
Young Boost 试验将 2004 至 2011 年纳入的 2421 例 ≤50 岁保乳治疗乳腺癌患者随机分为 26 Gy 与 16 Gy 瘤床加量组,主要终点为局部复发,美容效果为次要终点。4 年时标准加量组三种评分方法的美容效果均显著更优(满意美容效果 ±65% vs 55%)。光子加量、高加量剂量、放疗前美容效果差、大加量体积和辅助化疗显著恶化美容效果。
要点
- 4 年时标准加量组满意美容效果 ±65%,高于 55%。
- 光子加量、高加量剂量、基线美容差、大加量体积和辅助化疗显著恶化美容效果。
- 作者认为上述结果可用于制定改善美容效果的策略。
核心结论
- 美容效果不良的重要危险因素为使用光子加量而非电子加量、高加量剂量、基线美容效果、辅助化疗和加量体积。
- 作者认为这些结果可用于制定旨在改善美容效果的策略。
研究设计与样本
- Young Boost 试验(YBT)为随机试验,2004 至 2011 年纳入 2421 例 cT1-2N0-2a 乳腺癌患者。
- 患者 ≤50 岁、接受保乳治疗,随机分为 26 Gy 加量剂量组与 16 Gy 加量剂量组,主要终点为局部复发,美容效果为次要终点。
- 美容效果由患者和医生主观评分,并使用 BCCT.core 客观评分,在基线、治疗后 1 年和 4 年进行评估。
- 基于客观 BCCT.core 评分,采用比例优势模型分析美容效果不良的潜在危险因素。
主要发现
- 4 年时标准加量组三种评分方法的美容效果均显著更优(满意美容效果 ±65% vs 55%)。
- 光子加量、高加量剂量、放疗前美容效果差、大加量体积和辅助化疗显著恶化美容效果。
关键数值与推荐
- 4 年时标准加量组满意美容效果 ±65%,另一加量组为 55%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the Young Boost trial (YBT), breast cancer patients ≤50 years of age, treated with breast conserving therapy (BCT) were randomized between a 26 Gy boost dose and a 16 Gy boost dose, with local recurrence as primary and cosmetic outcome (CO) as secondary endpoint. Data of the YBT was used to investigate which factors are related with worse cosmetic outcome after BCT. METHODS: From 2004 to 2011, 2421 cT1-2N0-2a breast cancer patients were randomized. CO was scored subjectively by the patient and physician, and objectively using BCCT.core: at baseline, one and four years after treatment. Associations between potential risk factors for worse cosmetic outcome, based on the objective BCCT.core, were investigated using a proportional odds model. RESULTS: At four years, CO was significantly better in the standard boost group for all three scoring methods (satisfied CO ±65% vs 55%). A photon boost, high boost dose, poor cosmesis before radiation therapy, large boost volume and adjuvant chemotherapy significantly deteriorated CO. CONCLUSION: Important risk factors for worse CO were the use of a photon boost instead of an electron boost, a high boost dose, cosmesis at baseline, adjuvant chemotherapy and boost volume. These results can be used to define strategies aimed at improving CO.
引用
- Brouwers PJAM, van Werkhoven E, Bartelink H, et al. Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial. Radiother Oncol. 2018. PMID: 29980320. doi:10.1016/j.radonc.2018.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。